Medical News Today (Free subscription) | 25/11/2008
Exelixis, Inc. (Nasdaq:EXEL) today announced that Bristol-Myers Squibb Company (NYSE:BMY) has exercised its option to develop and commercialize Exelixis' investigational new drug (IND) candidate XL413, a selective inhibitor of Cdc7.
Business Wire (Free subscription) | 24/11/2008
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq:EXEL) today announced that Bristol-Myers Squibb Company (NYSE:BMY) has exercised its option to develop and commercialize Exelixis' investigational
Red Orbit (Free subscription) | 12/11/2008
CLEVELAND, Nov. 12, 2008 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) today announced the achievement of another clinical development milestone related to its discovery alliance with Bristol-Myers Squibb Company (NYSE:BMY).
Red Orbit (Free subscription) | 03/11/2008
Bristol-Myers Squibb Company and the Bristol-Myers Squibb Foundation have announced plans to award $1.4 million in grants focused on hepatitis C prevention and education and the mitigation of the disease in four Asian countries.
Seeking Alpha China (Free subscription) | 23/10/2008
Bristol Myers Squibb Company (BMY) Q3 FY08 Earnings Call Complete Story »
Business Wire (Free subscription) | 23/10/2008
NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY):
Market Wire - Investment Opinion (Free subscription) | 20/10/2008
LONDON (MARKET WIRE) MaybachFinancial.com is one of the fastest growing independent and unbiased research firms in the world. Through our numerous partnerships with many of the top investment minds in the world, we provide research on companies making a move in the markets. Investors seeking genuine analyst opinions on their investments for Snap-on Incorporated (NYSE: SNA), Dynegy Inc. (NYSE:...
Medical News Today (Free subscription) | 25/11/2008
NCCN (The National Comprehensive Cancer Network) has been awarded a $1.5 Million grant from Bristol-Myers Squibb Company and ImClone Systems Incorporated to fund research on the antibody cetuximab in patients with bladder cancer. The novel targeted therapy has proven effective in various other types of cancer including colorectal and head and neck. The University of Michigan Comprehensive...
Business Wire (Free subscription) | 24/11/2008
FORT WASHINGTON, Pa.--(BUSINESS WIRE)--The National Comprehensive Cancer Network (NCCN), Bristol-Myers Squibb Company and ImClone Systems Incorporated have entered into a collaboration to conduct a multi-institutional,
Market Wire - Investment Opinion (Free subscription) | 18/11/2008
WESTON, FL (MARKET WIRE) Wall Street News Alert's "stocks to watch" this morning are: CleanTech Biofuels, Inc. (OTCBB: CLTH), Level 3 Communications, Inc. (NASDAQ: LVLT), Bristol-Myers Squibb Company (NYSE: BMY) and Suncor Energy Inc. (NYSE: SU).
Red Orbit (Free subscription) | 06/11/2008
Exelixis, a development-stage biotechnology company, has signed an extension of the company's research collaboration agreement with Bristol-Myers Squibb Company to discover novel therapies targeted against the liver X receptor, a nuclear hormone receptor implicated in a variety of cardiovascular and metabolic disorders.
Medical News Today (Free subscription) | 06/11/2008
Sanofi-aventis (NYSE: SNY) and Bristol-Myers Squibb Company (NYSE: BMY) announced today that the American Heart Journal published the rationale and design of the ongoing CURRENT-OASIS 7 trial, a study evaluating the effects of standard and higher-dosing regimens of Plavix® (clopidogrel bisulfate)
Business Wire (Free subscription) | 06/11/2008
PARIS AND PRINCETON, N.J.--(BUSINESS WIRE)--Sanofi-aventis (NYSE: SNY) and Bristol-Myers Squibb Company (NYSE: BMY) announced today that the American Heart Journal published the
Red Orbit (Free subscription) | 06/11/2008
Sanofi-aventis (NYSE: SNY) and Bristol-Myers Squibb Company (NYSE: BMY) announced today that the American Heart Journal published the rationale and design of the ongoing CURRENT-OASIS 7 trial, a study evaluating the effects of standard and higher-dosing regimens of Plavix(R) (clopidogrel bisulfate) and aspirin on cardiovascular outcomes and bleeding complications in patients with acute...
The Earth Times Online Newspaper (Free subscription) | 06/11/2008
PARIS AND PRINCETON, N.J. - Sanofi-aventis (NYSE: SNY) and Bristol-Myers Squibb Company (NYSE: BMY) announced today that the American Heart Journal published the rationale and design of the ongoing CURRENT-OASIS 7 trial, a study evaluating the effects of standard and higher-dosing reg
